

Stereoselective convergent synthesis of 24-substituted metabolites and analogues of vitamin D[☆]

Iván Cornella^a, Rosa M. Suárez^a, Antonio Mouriño^b,
José Pérez Sestelo^{a,1}, Luis A. Sarandeses^{a,*}

^a Departamento de Química Fundamental, Universidade da Coruña, E-15071 A Coruña, Spain

^b Departamento de Química Orgánica y Unidad Asociada al C.S.I.C., Universidade de Santiago de Compostela, E-15706 Santiago de Compostela, Spain

Abstract

The synthesis of vitamin D₃ active metabolites [24*R*,25-(OH)₂-D₃, 24*S*,25-(OH)₂-D₃ and 1α,24*R*,25-(OH)₃-D₃] and the first 24-aminovitamin D₃ derivatives [24*S*-benzoylamino-25-OH-D₃ and 24*S*-benzoylamino-1α,25-(OH)₂-D₃] are reported. The stereogenic center at C-24 was generated through ultrasonically induced aqueous conjugate addition of iodide **8** to dioxolanone **6** or oxazolidinone **7**. The vitamin D triene system was constructed using the Lythgoe approach. The synthetic route, which is both short (6 or 7 steps from iodide **8**) and efficient (32–45% overall yield), constitutes a practical method for the preparation of 24-functionalized metabolites and analogues of vitamin D₃. The ultrasonically induced conjugate addition in the key step provides a novel example of a highly stereoselective reaction promoted by the zinc–copper couple in aqueous media.

© 2004 Elsevier Ltd. All rights reserved.

Keywords: Stereoselective synthesis; Conjugate addition; Aqueous media; Zinc–copper couple; 24-Hydroxyvitamin D; 24-Aminovitamin D

1. Introduction

Vitamin D₃ (**1a**) produces biological responses after transformation by successive stereospecific enzymatic hydroxylations into the major active metabolites 1α,25-(OH)₂-D₃ (**1b**, calcitriol, Fig. 1) and 24*R*,25-(OH)₂-D₃ (**1c**, secalciferol) [1]. These metabolites interact with specific protein vitamin D receptors (VDRs) in the cell nucleus (VDR_{nuc}) or in the membrane (VDR_{mem}) and give rise to the biological responses via genomic or nongenomic pathways [2,3]. Calcitriol and secalciferol are involved in a wide range of biological functions such as calcium homeostasis, cellular differentiation and proliferation processes, as well as other functions related to the immune system. However, the utility of these compounds as drugs in the treatment of tumors and skin diseases is limited since effective doses provoke undesirable calcemic side effects [1]. For this reason, the search for vitamin D₃ analogues with selective biological function, i.e. a low calcemic effect and

high activity as a cellular differentiation agent, has been extensively pursued in the last two decades [4,5].

Bearing in mind the influence of the hydroxyl groups at C-24 or C-25 on both the binding to the vitamin D receptor and the associated biological responses [6,7], we considered that replacement of one of these groups by another polar unit, particularly an amino group or derivative thereof, could give rise to novel analogues with a modified affinity for the VDR and hence different biological activity. The development of effective routes for the synthesis of these metabolites and analogues was envisaged as a worthwhile goal.


As part of our long-term programme devoted to the synthesis of vitamin D analogues and metabolites, as well as to the rational understanding of related biological functions, we focused our attention on the development of an efficient and stereoselective approach to 24-substituted vitamin D₃ metabolites and analogues. Several years ago we reported an efficient synthesis of the calcitriol side chain by means of an ultrasonically induced zinc–copper conjugate addition to α,β-unsaturated systems in aqueous media [8–11]—reaction conditions developed by Luche in the eighties [12,13]. The method was employed for the synthesis of calcitriol and 25-dialkyl analogues. Herein we report the use of this methodology for the stereoselective synthesis of 24,25-dihydroxyvitamin D metabolites and 24-amino-25-hydroxyvitamin D analogues.

[☆] Presented at the 12th Workshop on Vitamin D (Maastricht, The Netherlands, 6–10 July 2003).

* Corresponding author. Tel.: +34-981-167000; fax: +34-981-167065.

E-mail address: qfsarand@udc.es (L.A. Sarandeses).


¹ Co-corresponding author.

Fig. 1. Vitamin D₃ (**1a**), calcitriol (**1b**) and secalciferol (**1c**).

2. Results and discussion


For the stereoselective synthesis of 24,25-dihydroxyvitamin D₃ metabolites (**1c–e**), we considered the retrosynthetic analysis depicted in Scheme 1. The conjugated vitamin D triene system would be constructed following the Lythgoe approach [14] from 24-functionalized ketones **2** or **3** and the known phosphine oxides **4** or **5**. The 24-functionalized ketones **2** and **3** would be prepared by stereoselective conjugate addition between the known iodide **8** and Seebach's dioxolanone **6** (for the synthesis of 24,25-dihydroxy metabolites) or oxazolidinone **7** (for the synthesis of 24-amino-25-hydroxy derivatives).

The synthesis starts with iodide **8**, which contains the CD-rings of the vitamin D structure, and Seebach's dioxolanone **6**, which was prepared as both enantiomers [(+)-**6** and (–)-**6**] from enantiomerically pure lactic acid [15–17], or Seebach's oxazolidinone **7**, which was prepared from natural (*S*)-alanine [18]. Our retrosynthetic analysis was tested by performing the sonochemically induced aqueous zinc–copper conjugate addition of iodide **8** to the dioxolanone enantiomer (+)-**6**. Remarkably, the 1,4-




Scheme 2. Diastereoselective conjugate addition.

conjugate addition product **9** was obtained as a *cis:trans* mixture of diastereomers in an 11:1 ratio [83% de, major diastereomer: (24*R*)] and 70% yield (Scheme 2). The stereochemistry of the major diastereomer was assigned *cis* (24*R*) on the basis of the NMR assignments described by Axon and Beckwith [19]. When the reaction was performed with the dioxolanone enantiomer (–)-**6**, under the same experimental conditions, the conjugate addition product **10** was obtained in similar yield (74%) and stereoselectivity [*cis:trans* ratio of 13:1, 86% de, major diastereomer: (24*S*)]. This result proves that the stereoselectivity of the reaction is independent of the chirality of the iodide and that a remarkable, highly diastereoselective protonation of the enolate in aqueous media occurs [20,21]. On the other hand, ultrasonically induced conjugate addition of iodide **8** to methyleneoxazolidinone (–)-**7**, promoted by a zinc–copper



Scheme 1. Retrosynthetic analysis.

Scheme 3. Synthesis of 24R,25-(OH)₂-D₃ (**1c**) and 24S,25-(OH)₂-D₃ (**1d**).


couple in aqueous ethanol, afforded oxazolidinone **11** as a *cis:trans* mixture of diastereomers in a 4.9:1 ratio [66% de, major diastereomer: (24S)] and 74% yield. This result proves the efficiency of dioxolanones and oxazolidinones as chiral building blocks in the aqueous zinc–copper sonochemical conjugate addition and allows, in this case, the stereoselective introduction of a heteroatom at the C-24 position of the vitamin D structure.


The synthesis of the 24R,25-(OH)₂-vitamin D₃ metabolite (**1c**, secalciferol) and its 24S epimer (**1d**) involved initial cleavage of the protected α -hydroxyacid in **9** and **10**. The C-26 and C-27 methyl groups of the vitamin D side chain were introduced by reaction with MeMgBr and separation of the major stereoisomer (24R or 24S, respectively) by crystallization or chromatography (Scheme 3). Protection of the 24,25-diol unit as a ketal with acetone and subsequent oxidation of the hydroxyl group at the C-8 position afforded the ketones **16** or **17**. A Wittig–Horner reaction between ketones **16**–**17** and the anion of the phosphine oxide of **4**, which contained the vitamin D ring A, generated by treatment with *n*-BuLi at low temperature, followed by treatment with TBAF and the cationic resin AG[®] 50W-X4 afforded, in 7 steps from iodide **8**, the 24R,25-(OH)₂-D₃ (**1c**, secalciferol) in 32% overall yield, and 24S,25-(OH)₂-D₃ (**1d**) in 38% overall yield [20].

To further exploit the synthetic utility of this approach, we also synthesized the vitamin D₃ metabolite 1 α ,24R,25-(OH)₃-D₃ (**1e**, Scheme 4). This is an active metabolite that is generated in vivo from calcitriol, in vitro from secalciferol and has preferential biological action in the transport of calcium in the intestine [22]. A Wittig–Horner reaction between ketone **16** and the anion of the 1 α -hydroxylated

phosphine oxide **5** [23], generated at low temperature with *n*-BuLi, followed by deprotection with TBAF and treatment with the resin AG[®] 50W-X4 yielded the desired metabolite 1 α ,24R,25-(OH)₃-D₃ (**1e**) in 40% overall yield from **8** [20].

The synthesis of 24-amino-25-hydroxy analogues of vitamin D₃ was accomplished starting from the conjugate addition product **11** (Scheme 5). The first step in the transformation of oxazolidinone **11** into the desired 24-aminovitamin D₃ derivatives involved cleavage of the oxazolidinone ring and introduction of the C-26 and C-27 vitamin D₃ methyl groups. Both objectives were achieved

Scheme 4. Synthesis of 1 α ,24R,25-(OH)₃-D₃ (**1e**).



Scheme 5. Synthesis of 24S-benzoylamino-25-OH-D₃ (**26**) and 24S-benzoylamino-1 α ,25-(OH)₂-D₃ (**27**).

in a single step by reaction of **11** with methylmagnesium bromide to afford the 24S-benzoylamino derivative **21** in optically pure form after crystallization (80% yield). Oxidation of alcohol **21** with PDC (91%) followed by protection of the 25-hydroxyl group with TESOTf gave ketone **23** in 99% yield. A stereoselective Wittig–Horner reaction between ketone **23** and the anion of phosphine oxide **4**, generated by treatment with *n*-BuLi at low temperature, afforded the protected vitamin D analogue **24** (80%). Deprotection with TBAF gave the first amino derivative of vitamin D₃, 24S-benzoylamino-25-hydroxyvitamin D₃ (**26**), in 96% yield (6 steps from iodide **8**, 36% overall yield) [21].

A similar route was used to prepare the 1 α -hydroxylated analogue of **26** from ketone **23** (Scheme 5). Wittig–Horner reaction of ketone **23** with the anion of 1 α -hydroxylated phosphine oxide **5** gave the protected vitamin **25** in 95% yield. Deprotection with TBAF gave the desired vitamin analogue, 24S-benzoylamino-1 α ,25-dihydroxyvitamin D₃ (**27**), in 6 steps and 45% overall yield from iodide **8** [21].

In summary, we describe here the first stereoselective convergent synthesis of the 24,25-dihydroxyvitamin D₃ metabolites 24R,25-(OH)₂-D₃ (**1c**), 24S,25-(OH)₂-D₃ (**1d**) and 1 α ,24R,25-(OH)₃-D₃ (**1e**), and the first synthetic approach to 24-aminovitamin D₃ derivatives (**26** and **27**). The synthetic approach is both short and efficient—six or seven steps from known iodide **8** and 32–45% overall yield—and is a practical method for the synthesis of these natural metabolites and other 24-functionalized analogues. The key step in the synthesis is a novel diastereoselective conjugate addition promoted by the zinc–copper couple in aqueous media. Efforts to explore the scope of this reaction are in progress, as is the synthesis of other 24-aminovitamin D₃ derivatives and related analogues from other chiral α,β -unsaturated systems.

Acknowledgements

We are grateful to the Xunta de Galicia (PGIDT01PXI10-307PR) and DIGICYT (Spain, SAF2001-3187) for financial support. R.M.S. thanks the Ministerio de Educación Cultural y Deporte (Spain) for a predoctoral fellowship (FPU). I.C. acknowledges a predoctoral fellowship from the University of A Coruña.

References

- [1] D. Feldman, F.H. Glorieux, J.W. Pike (Eds.), Vitamin D, Academic Press, New York, 1997.
- [2] A.W. Norman, 25(OH)₂D₃: past, present, and future, J. Bone Miner. Res. 13 (1998) 1360–1369.
- [3] A.W. Norman, H.L. Henry, J.E. Bishop, X.-D. Song, C. Bula, W.H. Okamura, Different shapes of the steroid hormone 1 α ,25(OH)₂-vitamin D₃ act as agonists for two different receptors in the vitamin D endocrine system to mediate genomic and rapid responses, Steroids 66 (2001) 147–158.
- [4] W.H. Okamura, J.A. Palenzuela, J. Plumet, M.M. Midland, Vitamin D: structure-function analyses and the design of analogs, J. Cell. Biochem. 49 (1992) 10–18.
- [5] R. Bouillon, W.H. Okamura, A.W. Norman, Structure-function relationships in the vitamin D endocrine system, Endocr. Rev. 16 (1995) 200–257.
- [6] H. Dai, G.H. Posner, Synthetic approaches to vitamin D, Synthesis (1994) 1383–1398.
- [7] G.-D. Zhu, W.H. Okamura, Synthesis of vitamin D (calciferol), Chem. Rev. 95 (1995) 1877–1952.
- [8] J.L. Mascareñas, L.A. Sarandeses, L. Castedo, A. Mouriño, Palladium-catalyzed coupling of vinyl triflates with enynes and its application to the synthesis of 1 α ,25-dihydroxyvitamin D₃, Tetrahedron 47 (1991) 3485–3498.
- [9] J.L. Mascareñas, J. Pérez Sestelo, L. Castedo, A. Mouriño, A short, flexible route to vitamin D metabolites and their side chain analogs, Tetrahedron Lett. 32 (1991) 2813–2816.
- [10] J. Pérez Sestelo, J.L. Mascareñas, L. Castedo, A. Mouriño, Ultrasonically induced conjugate addition of iodides to electron-deficient olefins and its application to the synthesis of side-chain

- analogs of the hormone $1\alpha,25$ -dihydroxyvitamin D_3 , J. Org. Chem. 58 (1993) 118–123.
- [11] J. Pérez Sestelo, J.L. Mascareñas, L. Castedo, A. Mouriño, A short, flexible approach to vitamin D_3 analogs with modified side chains, Tetrahedron Lett. 35 (1994) 275–278.
- [12] C. Petrier, C. Dupuy, J.L. Luche, Conjugate additions to α,β -unsaturated carbonyl compounds in aqueous media, Tetrahedron Lett. 27 (1986) 3149–3152.
- [13] C. Dupuy, C. Petrier, L.A. Sarandeses, J.L. Luche, Ultrasound in organic synthesis. 19. Further studies on the conjugate additions to electron deficient olefins in aqueous media, Synth. Commun. 21 (1991) 643–651.
- [14] B. Lythgoe, Synthetic approaches to vitamin D and its relatives, Chem. Soc. Rev. (1980) 449–475.
- [15] D. Seebach, R. Naef, G. Calderari, α -Alkylation of α -heterosubstituted carboxylic acids without racemization. EPC-syntheses of tertiary alcohols and thiols, Tetrahedron 40 (1984) 1313–1324.
- [16] D. Seebach, A. Fadel, N,O-Acetals from pivalaldehyde and amino acids for the α -alkylation with self-reproduction of the center of chirality. Enolates of 3-benzoyl-2-(*tert*-butyl)-1,3-oxazolidin-5-ones, Helv. Chim. Acta 68 (1985) 1243–1250.
- [17] J. Zimmermann, D. Seebach, Brominations of cyclic acetals from α -amino acids and α - or β -hydroxy acids with N-bromosuccinimide, Helv. Chim. Acta 70 (1987) 1104–1114.
- [18] A.L.J. Beckwith, S.G. Pyne, B. Dickic, C.L.L. Chai, P.A. Gordon, B.W. Skelton, M.J. Tozer, A.H. White, An efficient synthesis of (2S)- and (2R)-*N*-benzoyl-2-*tert*-butyl-4-methyleneoxazolidin-5-one, Aust. J. Chem. 46 (1993) 1425–1430.
- [19] J.R. Axon, A.L.J. Beckwith, Diastereoselective radical addition to methyleneoxazolidinones: an enantioselective route to α -amino acids, J. Chem. Soc., Chem. Commun. (1995) 549–550.
- [20] J. Pérez Sestelo, I. Cornella, O. de Uña, A. Mouriño, L.A. Sarandeses, Stereoselective convergent synthesis of 24,25-dihydroxyvitamin D_3 metabolites: a practical approach, Chem. Eur. J. 8 (2002) 2747–2752.
- [21] J. Pérez Sestelo, O. de Uña, A. Mouriño, L.A. Sarandeses, Synthesis of the first 24-aminovitamin D_3 derivatives by diastereoselective conjugate addition to a chiral methyleneoxazolidinone in aqueous media, Synlett (2002) 719–722.
- [22] S. Ishizuka, S. Ishimoto, A.W. Norman, Isolation and identification of $1\alpha,25$ -dihydroxy-24-oxovitamin D_3 $1\alpha,25$ -dihydroxyvitamin D_3 26,23-lactone and $1\alpha,24(S),25$ -trihydroxyvitamin D_3 : in vivo metabolites of $1\alpha,25$ -dihydroxyvitamin D_3 , Biochemistry 23 (1984) 1473–1478.
- [23] A. Mouriño, M. Torneiro, C. Vitale, S. Fernández, J. Pérez Sestelo, S. Anné, C. Gregorio, Efficient and versatile synthesis of A-ring precursors of $1\alpha,25$ -dihydroxy-vitamin D_3 and analogs. Application to the synthesis of Lythgoe-Roche phosphine oxide, Tetrahedron Lett. 38 (1997) 4713–4716.